Prescription medicine
Vericiguat Brand names: Verquvo
Vericiguat (Verquvo) is a prescription medicine with an FDA approval on record since 2021. No generic is listed; pharmacies paid $22.72 per Verquvo 10 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- Boxed warning
Check it at the source: the vericiguat FDA label on DailyMed (effective January 21, 2026, Merck Sharp & Dohme LLC); the NDA 214377 record on Drugs@FDA; every vericiguat label on DailyMed.
Highlights of the record
FDA label of January 21, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
EMBRYO-FETAL TOXICITY.
Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Use in Specific Populations (8.3) ]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Do not administer VERQUVO to a pregnant female because it may cause fetal harm. ( 4 , 5.1 , 8.1 ) Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment.
Used for
From the label: indications and usageVERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ].
Forms and strengths
- 2.5 mg
- 5 mg
- 10 mg
Film-coated tablet.
On the market
- Earliest approval on file
- January 19, 2021 Verquvo, Msd; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- November 26, 2032 Verquvo tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $22.72 per tablet Verquvo 10 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 966 through July 30, 2026
What is vericiguat used for?
From the label: indications and usageVERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ]. VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Conditions named in the indications of vericiguat's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Soluble Guanylate Cyclase Stimulator.
Source: FDA drug label (VERQUVO), NDA214377 (Msd), as published by Merck Sharp & Dohme LLC, effective January 21, 2026 (SPL set 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d), via openFDA; the full label on DailyMed
What does the patient leaflet for vericiguat say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about VERQUVO?VERQUVO may cause birth defects if taken during pregnancy. Females must not be pregnant when they start taking VERQUVO. Females who are able to get pregnant: Your healthcare provider will do a pregnancy test to make sure that you are not pregnant before you start taking VERQUVO. You must use effective forms of birth control during treatment and for 1 month after you stop treatment with VERQUVO. Talk to your healthcare provider about forms of birth control that you may use to prevent pregnancy during treatment with VERQUVO. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with VERQUVO. There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Patients should report any exposure to VERQUVO during pregnancy by calling 1-877-888-4231 or at https://pregnancyreporting.verquvo-us.com.
From the patient leaflet: How should I store VERQUVO?Store VERQUVO at room temperature between 68°F to 77°F (20°C to 25°C). Keep VERQUVO and all medicines out of the reach of children.
Source: FDA drug label (VERQUVO), NDA214377 (Msd), as published by Merck Sharp & Dohme LLC, effective January 21, 2026 (SPL set 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d), via openFDA; the full label on DailyMed
Is there a generic for vericiguat (Verquvo)?
No generic vericiguat is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 6 patents for Verquvo tablets: the compound patent runs to November 26, 2032. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2021 earliest approval on file
- 2032 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for vericiguat (Verquvo)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $22.72 per Verquvo 10 mg tablet, up 2% from $22.20 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Verquvo 10 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Verquvo 10 mg tablet | Brand | $22.72 per tablet | $681.74 | +2% |
| Verquvo 2.5 mg tablet | Brand | $22.73 per tablet | $681.81 | +3% |
| Verquvo 5 mg tablet | Brand | $22.73 per tablet | $681.81 | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the vericiguat label say about other medicines?
The vericiguat label names no other medicine on this site. The labels of 1 other medicine name vericiguat. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Source: FDA drug label (VERQUVO), NDA214377 (Msd), as published by Merck Sharp & Dohme LLC, effective January 21, 2026 (SPL set 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d), via openFDA; the full label on DailyMed
What do FAERS reports show for vericiguat?
The FDA Adverse Event Reporting System holds 966 reports that list vericiguat among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 148 are coded as a death and 244 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as vericiguat?
16 other medicines are given the same way (oral) and in the same FDA class as vericiguat or labeled mainly for the same use (heart failure), the same class first. Heart failure lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Carvedilol | Heart failure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Spironolactone | Heart failure | 38 labelers | $0.0426 per tablet 25 mg tablet | A presentation being discontinued |
| Hydrochlorothiazide | Heart failure | 44 labelers | $0.0115 per tablet 25 mg tablet | A presentation being discontinued |
| Furosemide | Heart failure | 33 labelers | $0.026 per tablet 20 mg tablet | In shortage |
| Sacubitril and valsartan | Heart failure | 27 labelers | $0.533 per unit 49-51 mg | No current entry |
| Bumetanide | Heart failure | 24 labelers | $0.108 per tablet 1 mg tablet | Resolved |
| Digoxin | Heart failure | 21 labelers | $0.133 per tablet 125 mcg tablet | No current entry |
| Ivabradine | Heart failure | 11 labelers | $0.761 per tablet 5 mg tablet | A presentation being discontinued |
Every medicine labeled for the same conditions as vericiguat
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to vericiguat
- 16 medicines for the same use
- Other soluble guanylate cyclase stimulators
- the pharmacologic class, with prices and generics
- Vericiguat side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other